{"symbol":"ABBV","fiscalQuarter":"Q4-2022","reportDate":"2023-02-09","reportTime":"BMO","status":"reported","company":{"name":"AbbVie Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/ABBV/earnings/Q4-2022","postBrief":{"headline":"AbbVie Beats on EPS, Stock Up 2.83%","keyNumbers":[{"metric":"EPS","actual":"$3.60","expected":"N/A","surprise":"+1.75%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted the strong performance of key products.","They emphasized ongoing commitment to innovation and pipeline development.","There was a focus on maintaining market leadership despite competitive pressures."],"summary":"Overall, management expressed confidence in their product portfolio and future growth. They acknowledged challenges but remain focused on strategic initiatives."},"guidanceChanges":{"summary":"No forward guidance was provided in this earnings report.","changes":[]},"whatItMeans":"AbbVie's earnings report showed a positive surprise in EPS, which contributed to a 2.83% increase in stock price. The company\u2019s management conveyed a sense of cautious optimism about future growth, particularly in their key products. However, the lack of revenue data and guidance leaves some uncertainty for investors.","metaDescription":"AbbVie Inc (ABBV) Q4 2022 earnings: EPS beat by 1.75%. Stock up 2.83%. Full breakdown."}}